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Abstract
Percutaneous coronary intervention (PCI) is an integral part of the treatment of coronary artery
disease. The most common complication of PCI, bleeding, typically occurs at the vascular access
site and is associated with short-term and long-term morbidity and mortality. Periprocedural
bleeding also represents the primary safety concern of concomitant antithrombotic therapies
essential for PCI success. Use of radial access for PCI reduces procedural bleeding and hence may
change the risk profile and net clinical benefit of these drugs. This new drug-device safety
interaction creates opportunities to advance the safe and effective use of antithrombotic agents
during PCI. In June 2010 and March 2011, leaders from government, academia, professional
societies, device manufacturing, and pharmaceutical industries convened for 2 think tank
meetings. Titled TREAT I and II, these forums examined approaches to improve the overall safety
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of PCI by optimizing strategies for antithrombotic drug use and radial artery access. This article
summarizes the content and proceedings of these sessions.
Today we are at a critical moment for innovation. Despite the struggling U.S.
economy, American pharmaceutical, biotech[nology], and medical device
companies have maintained a competitive advantage in the global marketplace...
but there are signs that the health of these industries may be at increasing
risk...Today's medical product pipeline does not have enough new products to
sustain the health of the industry in the long-term to address many of the chronic
diseases afflicting Americans every day... We must act now and work together to
capitalize on... groundbreaking science in order to bring safer and more effective
treatments to American families and keep our position as the global leader in
scientific innovation.
- Dr Margaret Hamburg, Commissioner of the Federal Food and Drug
Administration (FDA), “A Note from the Commissioner,” Driving Biomedical
Innovation: Initiatives for Improving Products for Patients, October 5, 2011.
Safety is a global priority for the development of drugs and devices. This emphasis
represents not only interest in optimizing patient outcomes but also recognition of safety
concerns as a major barrier to product innovation, development, use, and marketing. Over
the last 40 years, more than 120 compounds were withdrawn from the market and from drug
development programs worldwide.1-3 Growing pressures to identify rare but catastrophic
clinical events affecting “off-target” organ systems have inflated development costs for new
therapeutics, and mounting demands for safety demonstration siphon resources from
discovery and innovation. The detailed and prolonged assessments for cardiac safety have
contributed to the decline in a number of new therapies approved in the United States,
despite record investments in biomedical research.4
In 2004, the US FDA introduced its Critical Path Initiative to address the widening gap
between scientific discoveries and their translation into medical products. Because concerns
about cardiovascular safety can challenge medical product innovation, the Duke Clinical
Research Institute (DCRI), Durham, NC, entered into a memorandum of understanding with
the FDA to form the Cardiac Safety Research Consortium (CSRC) (www.cardiac-
safety.org), a transparent Critical Path public-private partnership of representatives from
government, industry, and academia. The CSRC was created to support investigation of
cardiovascular safety to facilitate cardiac safety–related regulatory process improvements.
One of the key mechanisms through which the CSRC functions is the coordination of think
tank, or public forums that promote cross-sector scientific collaboration as well as sharing of
data and expertise regarding challenging topics in cardiac safety. These think tanks have
produced research projects focused on removing barriers to innovation, benefiting
collaborating partners and the public health.5,6
Bleeding associated with adjunctive drugs in the setting of percutaneous coronary
intervention (PCI) is a consistently challenging aspect of cardiovascular safety.
Percutaneous coronary intervention is an integral part of the treatment of coronary artery
disease, improving mortality in acute coronary syndromes and relieving ischemic symptoms
in patients with stable coronary artery disease.7 According to market estimates, each year
more than 1 million patients in the United States undergo PCI, with approximately 600,000
of these procedures performed in the inpatient setting.8 Intracoronary stents are frequently
implanted during PCI to reduce the risk of abrupt vessel closure and the need for repeat
procedures. Stents are inherently prothrombotic until fully endothelialized and require short-
and long-term concomitant antithrombotic therapies, such as glycoprotein IIb/IIIa inhibitors
and dual-antiplatelet therapy, to prevent stent thrombosis. Although largely effective, these
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therapies also cause bleeding. Procedural success reflects interactions among patient, drug,
and device, and the clinical benefit of antithrombotic regimens may be offset primarily by
bleeding events, particularly those related to vascular access site complications.
To address the issue of antithrombotic therapy and bleeding complications associated with
PCI, 2 think tank meetings, titled TREAT I and II, were organized at the FDA headquarters
in White Oak, MD, on June 23, 2010, and March 7, 2011. These forums were the result of
collaboration among the CSRC, the DCRI, the American College of Cardiology Foundation
(ACCF), the Society for Cardiac Angiography and Interventions (SCAI), the National Heart
Lung Blood Institute, the FDA, and national and international representatives from
academia, device manufacturing, and pharmaceutical industries (see the online Appendix).
The focus of these think tanks was to reevaluate optimal antithrombotic strategies in light of
reduced PCI bleeding risk associated with contemporary radial vascular access. Participants
from TREAT explored the “obligatory drug-device safety interaction” paradigm by
reversing the traditional perspective of using drugs to enhance procedural safety into a novel
view in which modification of the procedural approach improves the safety and net clinical
benefit of antithrombotic therapies. Participants examined strategies for demonstrating
whether radial artery access changes the optimal risk-benefit ratio for currently
recommended anticoagulant and antiplatelet strategies. The potential effects of transradial
PCI on patient care and hospital resource use, as well as barriers to the widespread adoption
of the radial technique, were also examined. This white paper summarizes the content and
proceedings of the TREAT think tank discussions.
Bleeding and PCI: an overview
Although definitions of bleeding vary among reports, periprocedural bleeding is a common
complication after PCI, with estimates of the incidence of major bleeding after PCI ranging
from 2.2% to 14%.9-12 Use of antithrombotic agents, important adjuncts to successful PCI,
has been limited by this bleeding.13,14 Overall rates of bleeding vary among drugs, but
vascular site bleeds represent an important proportion of all bleeding events.15 Kinnaird et
al10 performed a retrospective analysis of 12,029 PCIs and found 588 major and 1,394
minor bleeding events, of which 68% and 60%, respectively, were related to vascular access
in the form of hematomas or retroperitoneal bleeds. Data from pooled clinical trials found
that 925 (5.3%) of 17,393 patients undergoing PCI experienced a bleeding event classified
as Thrombolysis in Myocar-dial Infarction major/minor bleeding. Of these bleeding events,
54.3% involved the access site, 15.4% were from non–access sites, and 30.4% were from
unidentified sites.16
Percutaneous coronary intervention–related bleeding complications have important short-
and long-term consequences. Short-term consequences include prolonged hospital stay, need
for blood transfusions and surgical intervention, and interruption of antithrombotic therapy
otherwise needed for prevention of stent thrombosis and secondary ischemic events. The
long-term sequelae of bleeding include major adverse cardiac events, although a causal
relationship between bleeding and such outcomes has not been elucidated.10,17-20 Recent
analysis of data from the Acute Catheterization and Urgent Intervention Triage strategY
(ACUITY) trial showed that patients with major bleeding had significantly higher rates of
30-day mortality (7.3% vs 1.2%, P < .0001), composite ischemia (defined as death,
myocardial infarction [MI], or unplanned revascularization for ischemia; 23.1% vs 6.8%, P
< .0001), and stent thrombosis (3.4% vs 0.6%, P < .0001) compared with patients without
bleeding.17 Ndrepepa et al20 examined periprocedural bleeding in 4 randomized clinical
trials (RCTs) of the platelet glycoprotein IIb/IIIa receptor inhibitor abxicimab and found that
the 30-day occurrence of bleeding was an independent predictor of 1-year mortality (hazard
ratio [HR] 2.96, 95% CI 1.96-4.48, P < .001). Furthermore, both non–access site and access
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site bleeding after PCI are associated with mortality; there is an approximately 2-fold
increase in risk of 1-year mortality associated with non–access site vs access site bleeding
(HR 3.94 [95% CI 3.07-5.15, P < .0001] vs HR 1.82 [95% CI 1.17-2.83, P = .008]).16
Although there is a stronger association of non–access site bleeding with mortality,
reductions in overall bleeding risk and access site bleeding specifically remain important
targets for improving PCI outcomes.
Vascular access safety in women undergoing PCI
Women undergoing PCI are at increased risk for antithrombotic drug-related bleeding and
vascular complications. Women have higher rates of bleeding than men after PCI,21,22 and
multiple studies show that female sex independently predicts bleeding and death after
PCI.23,24 Although overdosing of antithrombotic medications theoretically contributes to the
increased bleeding experienced by women after PCI, data suggest that excessive medication
accounts for only 25% of the sex-related difference in bleeding risk.25 In addition to higher
rates of post-PCI bleeding, women also have more frequent access site complications,
regardless of access site and use of vascular closure devices (Figure 1).26-31 Despite
available bleeding avoidance strategies, there exists a “risk-treatment paradox.” Data from
the National Cardiovascular Data Registry (NCDR) CathPCI Registry have shown that use
of vascular closure devices and antithrombotic medications with lower bleeding risk, such as
bivalirudin, are used less often in patients at higher risk for bleeding, including women.32
An overview of transradial PCI
The radial artery is small, superficial, easily compressible, and free of neighboring major
structures, making vascular complications and bleeding less frequent and more easily
managed than with femoral artery access. Randomized trials such as RadIal versus femorAL
access for coronary angiography or intervention in patients with acute coronary syndromes
(RIVAL) have shown that the radial approach is associated with reduced bleeding and
vascular complication rates compared with femoral access.33-35 In a large observational
study from the NCDR, Rao et al21 examined 593,094 PCI procedures and found that 0.19%
of patients undergoing radial access vs 0.70% of patients undergoing femoral access had
vascular complications. Additional benefits of transradial intervention (TRI) include faster
ambulation, greater comfort, and shorter hospital length of stay. A small, randomized trial
also found that TRI improved quality of life and was preferred by patients.36
Advantages of transradial access may also extend to longer-term outcomes. The Mortality
benefit Of Reduced Transfusion after PCIs via the Arm or Leg (MORTAL) study found that
among 38,872 PCI procedures, radial vs femoral access was associated with reduced rates of
blood transfusion (odds ratio [OR] 0.59, 95% CI 0.48-0.73) and 30-day and 1-year mortality
(OR 0.71 [95% CI 0.61-0.82] and OR 0.83 [95% CI 0.71-0.98], respectively).37 Other
randomized trials including RIVAL have not confirmed this mortality reduction associated
with radial access.
Despite several advantages offered by a transradial approach, adoption of this technology
has been relatively slow in the United States. In 2007, TRI accounted for only 1.32% of
procedures.21 As shown in Figure 2, recent data show that the use of radial access has
increased to 11% of PCIs (personal communication, NCDR) but still accounts for a small
minority of procedures. Difficulties with radial access and the documented “learning curve”
for TRI are important potential barriers to US uptake.38 The smaller radial artery may not
accommodate interventional catheters as easily as the femoral artery, and spasm, tortuosity,
and occlusion of the radial artery pose additional challenges. Compared with femoral
procedures, radial procedures have been associated with significantly increased rates of
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procedural failure, access site crossover, longer procedure times, greater use of contrast, and
higher radiation exposure.33,39 However, additional operator experience and movement
along the learning curve promote significant reductions in procedural time and radiation
dose,15,40 with a decrease in the odds of procedural failure of 32% for each 50 case increase
in PCI volume.41 Despite these data, some TRI operators remain discouraged by initial
technical difficulties and logistical challenges of converting catheterization laboratories
accustomed to femoral PCIs because hospital environments may not have necessary
equipment, and staff may initially lack knowledge regarding radial procedure setup and
patient care. In these settings, low operator or hospital procedure volume may limit the
adoption of a new technique.
Non-procedural factors have also been cited to explain the lack of US adoption of radial
artery access. One of the most often cited explanations has been the deficiency in transradial
exposure during fellowship training. There are no general guidelines for TRI training and,
specifically, no minimal volume requirements for competence. Moreover, radial artery
access was only recently included for the first time in the ACCF/American Heart
Association/SCAI guidelines for PCI as a class IIa (level of evidence: A) recommendation in
the November 2011 update.7 The paucity of radial vs femoral RCTs with US enrollment
may also contribute to both the reluctance to adopt TRI and its relatively late inclusion in
practice guidelines. Conversely, the lack of US operator experience may limit feasibility of
domestic RCTs of bleeding rates related to vascular access and concomitant drugs. There are
several approaches to address this important scientific gap.
A national transradial registry?
The FDA has recognized that most efficacy trials of antithrombotic agents predated routine
performance of TRI, and hence, bleeding rates of drugs used for femoral PCI procedures
might overestimate rates of TRI-associated bleeding. As a result, the FDA initially
expressed interest in a national transradial registry to compare different antithrombotic and
vascular access strategies to inform drug labeling. Such a database could use the NCDR's
CathPCI Registry as a backbone to permit rapid broad sampling of “real- world” clinical
practice across variations in antithrombotic treatment strategies. Designing nested studies
within the registry could also allow investigators or manufacturers to prospectively address
questions regarding potential interactions among patient factors, drug regimens, vascular
access sites, and bleeding rates. However, there were concerns that systematic differences in
drug regimens between transradial and femoral interventions might confound comparisons
between registry patients and historical controls. Observational data would likely be
insufficient to inform drug safety and would be limited in the amount of longitudinal data
that could be collected, motivating interest in RCTs of vascular access with close attention
to concomitant drug therapy.
Extending collaboration and efficiency through infrastructure: CSRC joins
with the NCRI
Discussion about ways to foster efficiency using existing registry infrastructure for a
prospective RCT centered on the National Cardiovascular Research Infrastructure (NCRI).
The DCRI and the ACCF have collaborated to develop a clinical research network to allow
investigators to take advantage of the data collection of the American College of
Cardiology's NCDR registries. The NCRI has been tasked with maintaining this centralized
research network. Multiple uses of such a powerful research instrument include site profiling
and recruitment, integrated randomization mechanisms, site training, and quality
improvement and education processes. Data elements use standardized definitions, and data
are entered once by sites with direct electronic transfer to the clinical trial database for
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analysis. Designing and executing a prospective, randomized study of vascular access using
such a collaborative research network would have many advantages such as reduced work
for site coordinators and enhanced quality of patient data.
Radial PCI study design: key issues and lessons from RIVAL
TREAT considered several key issues in designing a study of radial vs femoral PCI. One
proposed study design involved concomitant enrollment of patients in select dedicated
femoral and radial access sites. Comparative statistical analyses would then be conducted on
case-matched patients. However, such a study would not provide sufficient randomized data
to inform drug safety. Instead, consensus was reached that a RCT was preferable.
Organizational lessons from the international RIVAL trial were discussed with regard to
designing a US-based RCT of vascular access.35 In RIVAL, finding sites and operators with
equipoise suitable for randomization was challenging. Some experienced radialists with very
high (>90%) radial volume and significantly improved bleeding outcomes were strong
advocates of the benefits of TRI and considered randomization to femoral access unethical.
Patients and catheterization laboratory staff at high-radial-volume centers similarly exhibited
a strong preference for radial access and often refused randomization to a femoral approach.
Conversely, sites with operators using predominantly femoral access did not have technical
equipoise to randomize to radial access due to inexperience and the early learning curve.
The advantage of using only expert, high-volume operators, and dedicated sites would be the
testing of hypotheses using optimal practices. However, the generalizability of these
findings would be limited because they would be applicable to a small, select group of US
operators and would not account for the learning curve. High-volume operators may also use
different intraprocedural antithrombotic regimens than femoral operators, thus confounding
observed bleeding rates.
The site selection strategy in RIVAL targeted sites in transition from femoral to radial
access. The main advantage of this approach was the avoidance of both the learning curve
for high-volume femoralists and the lack of clinical equipoise with high-volume radialists.
Disadvantages of this strategy might be higher crossover rates, reduced statistical power to
detect differences between the 2 approaches on an intent-to-treat basis, and the potential to
underestimate the benefits of one approach over the other. Indeed, the results of RIVAL,
which were not available during the TREAT sessions, showed no difference with respect to
the primary composite end point of death, MI, stroke, and noncoronary artery bypass graft
surgery–related major bleeding at 30 days.35
Optimally, an RCT of vascular access would be focused on a question for which there is
clinical equipoise such that experienced radial and femoral operators would be willing to
participate. Such a design would permit observations about the potential impact of the radial
approach in the hands of its most experienced operators. In addition, results from this study
could help to provide benchmark metrics such as procedure times, contrast volume, and
radiation dose, which could be useful for best-practice guidelines and the evaluation of
training methods. Although this trial design would ideally favor inclusion of high-volume
operators in experienced centers, reliable identification of these expert operators/centers in
the United States would be difficult: operator and site volume for radial procedures are not
always correlated because many experienced radialists in the country constitute a minority
of practitioners at their sites. The NCDR's CathPCI Registry was suggested as a tool to
identify potential trial operator and site participants through its ability to profile radial PCI
volume. An added benefit of this approach would be the site's familiarity with the NCDR
case report form (CRF) that would serve as the basis for electronic trial data collection.
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Bleeding was chosen as one of the primary outcomes for the proposed transradial RCT, but
bleeding definitions remain controversial. Multiple definitions of bleeding based on both
clinical events and laboratory parameters currently exist and have been used inconsistently
in clinical trials including pivotal registration studies. The recently published Bleeding
Academic Research Consortium (BARC) definitions were developed to counter such
heterogeneity.42 There was consensus agreement that the primary bleeding end point for a
radial vs femoral access RCT should incorporate these definitions.
Nonbleeding outcomes were also recognized as key end points to capture. Evaluation of
procedural metrics including length of procedure, radiation dose, contrast volume, and
procedural success would allow for valuable comparisons between vascular access
approaches. Collecting specific drug information instead of general classes of antithrombotic
agents would provide the ability to assess the safety profiles of individual medications.
Meeting attendees also wanted to examine the impact of radial access on short-term quality
of life through earlier ambulation and less discomfort, as well as hospital resource use
through reduced length of hospital stay. Additional trial end points would include effects of
vascular complications on long-term outcomes and quality of life, such as residual arm
discomfort and radial arterial occlusion. However, specific instruments to measure these
quality of life effects currently do not exist and need to be developed and validated.
The inclusion of patients presenting with ST-segment elevation MI (STEMI) in a trial of
radial vs femoral access for PCI was debated. Operators from experienced radial centers
outside the US cited routine use of radial access for STEMI cases and clinical benefit of
such a vascular approach in this population.43 However, the generalizability of these
observations to US centers was thought to be limited because the lack of widespread radial
operator expertise and catheterization laboratory staff experience in the United States might
compromise STEMI door-to-balloon times and patient outcomes. The final decision was
thus made to exclude patients with STEMI from an RCT of vascular access. However, data
from multiple studies suggest that TRI used for STEMI may be associated with clinical
benefit, raising the possibility of revisiting this issue in the future.44-46
Identifying clinical equipoise: vascular access in women
The concept of clinical equipoise was fundamental to the identification of an appropriate
study population for a randomized trial of vascular access. All agreed that women would be
the one cohort for which this trial could be conducted with clinical equipoise (Table I).
Women have a greater risk of bleeding, particularly from the access site, but also have
smaller arteries that are more prone to spasm. Thus, the selection of optimal vascular access
strategy in this group remains unclear; the potential for women to benefit from less bleeding
with TRI could be offset by an increase in procedural failure or vascular complications. For
these reasons, some transra-dial interventionalists were more willing to randomize women to
assess the net clinical benefit of TRI in this high-risk population. Along with the decision to
use women as the study population came recognition of the need to capture data relevant to
the evaluation and treatment of cardiovascular disease in women. Such information would
include menopausal status, use of hormone replacement therapy, and a specific history of
vasospastic or autoimmune diseases, as well as measures of functional loss or debility
following PCI.
Study of Access Site for Enhancement of PCI for Women
The Study of Access Site for Enhancement of PCI for Women (SAFE-PCI for Women) trial,
a proof of concept study, was the result of a series of medical device safety and collaborative
research initiatives, including CSRC Critical Path think tank (Figure 3), that led to the
development of a study that addresses an important clinical question and leverages unique
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trial infrastructure. The trial was designed to be the first randomized study comparing the
transradial to transfemoral approach PCI with a focus specifically on women's health. The
SAFE-PCI trial also represents the first use of the NCRI clinical research network and the
initial application of the BARC bleeding definitions. Through recommendations for
contemporary procedural medication regimens, including use of bivalirudin and P2Y12
inhibitors, the investigators aim to determine clinically important outcomes in best-practice
scenarios.
The SAFE-PCI study population will include women undergoing elective PCI or presenting
with non–ST-segment elevation acute coronary syndromes. Patients will be randomized to
radial or femoral access and will have their procedures performed by operators experienced
in the assigned vascular approach. Data from the NCDR CathPCI Registry will be used for
site identification, CRF development, and data entry through automatic transfer of
information entered into CathPCI to the trial CRF. The primary end points for SAFE-PCI
will be bleeding according to BARC criteria (types 2, 3, or 5 bleeding)42 and vascular
complications (arteriovenous fistula, pseudoaneurysm, or arterial occlusion requiring
surgical intervention) at 72 hours postprocedure or by hospital discharge, as well as
procedural failure. Secondary end points for the trial will include assessments of procedural
metrics, quality of life, and the 30-day occurrence of death, vascular complications, or
unplanned revascularization. Full details of SAFE-PCI will be forthcoming in a separate
article.
Beyond SAFE-PCI
The SAFE-PCI for Women study represents one of several new directions for conducting
research on vascular access safety and for expanding uptake of TRI in the United States.
Using highly experienced radial operators in SAFE-PCI will provide some performance
metrics and standards that can potentially be used as benchmarks for quantifying progress
along the learning curve and measuring the impact of educational programs and other tools
such as simulators. The potential for global participation in TREAT programs could
leverage the far greater TRI experience outside the United States. Transradial intervention
uptake in the United States could also be aided by making available training courses and
Web sites for established interventionalists interested in adding TRI to their repertoire and
by exposing new interventional cardiology fellows to transradial catheterization during the
early stages of their training. To this end, one mechanism to achieve the latter goal might be
to revise and expand competency requirements specifically for TRI in the ACCF/SCAI Core
Cardiology Training Symposium guidelines. In addition, promoting a team approach that
educates interventionalists, catheterization laboratory staff, and referring physicians about
TRI and that emphasizes the overlap in use of standard catheterization equipment for both
femoral and radial PCI will be important in easing the transition of primarily femoral
laboratories to TRI.
Further innovation will be required to overcome the barriers to research posed by the
ongoing focus on cardiac safety. A number of pragmatic approaches to address these
obstacles have already been implemented, and renewed federal interest in cardiac safety is
evident in the many grants awarded as part of the American Recovery and Reinvestment Act
for comparative effectiveness research. Efforts have been made to streamline and ensure the
accuracy of data entry and transfer through the adoption of electronic health records,
computerized databases, and standardized data definitions. Increasing use of data from
registries and linkage of databases has also allowed for longitudinal assessment of outcomes.
Importantly, emphasis has been placed on the roles of professional societies and academia
for ensuring cardiac safety. Physician members of these organizations not only advocate for
their patients but also develop practice guidelines, accreditation standards, and policy
Hess et al. Page 8













documents, and they serve on drug safety monitoring boards and clinical events committees.
Professional societies and academic institutions additionally provide independent data
collection and analysis. To these efforts, the SAFE-PCI study, a randomized, controlled
clinical trial nested within an existing electronic data registry, will now add a new paradigm
for conducting patient-oriented research. This more efficient and less costly design may
have implications for fundamentally changing the construct of US-based clinical research.
Conclusions
In response to the current landscape of barriers to biomedical research, the CSRC was
launched to focus on cardiac safety and foster innovation by overcoming precompetitive
barriers through transparent dialogue and novel, collaborative research programs. An
important operational tool for the CSRC is the organization of think tank meetings
comprised of representatives from government, industry, and academia dedicated to
addressing specific issues related to cardiac safety of medical products. In one area of such
CSRC activities, the domain of drug-device safety interactions, the opposing risks of
thrombosis and bleeding associated with PCI procedures are central to overall
cardiovascular safety. The potential to change device technique to inform drug safety
labeling for antithrombotic compounds represents a novel area of obligatory drug-device
safety interactions. As illustrated in this white paper, the CSRC has facilitated important
dialogue leading to the creation of a novel RCT, SAFE-PCI, that will not only answer
important clinical questions in women's health but also serve as a proof of concept for using
efficient infrastructure and electronic data capture as a new paradigm for US clinical
research. Efforts such as these are in line with Commissioner Hamburg's vision for
restructuring the nation's current framework for biomedical innovation.
We know that the constant developments in science and technology—in fields as
diverse as genomics and nanotechnology—hold the promise of major therapeutic
advances. But, right now, we lack the ability to effectively translate many of those
developments into vital products for those who need them...FDA can help make
trials more efficient by qualifying biomarkers that accurately predict outcomes and
by encouraging innovative trial designs that are equally effective but less
burdensome and time-consuming... Our success will depend on out-reach and
collaboration. We must be active participants in research and development through
partnerships with academia, industry and other government agencies.
- Dr Margaret Hamburg, Remarks at the American Association for the
Advancement of Science Forum on Science and Technology Policy, May 14, 2010.
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Bleeding and vascular complications after PCI in men vs women. rPCI, radial PCI; f-PCI,
femoral PCI. From Rao et al.21
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Temporal trends in use of radial PCI in the United States since 2007. Data courtesy of
NCDR. QTR, quarter.
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Table I
Clinical equipoise for a RCT of vascular access in women
Favors radial approach Favors femoral approach
• Females are at higher risk for bleeding after PCI21 • Females have smaller radial arteries, which may contribute to procedural
failure (more prone to spasm, may not accommodate 6F systems)
• Females are at higher risk for vascular complications after
PCI21
• Females have higher rates of radial artery occlusion47
• Females are more likely to receive overdosing of
antithrombotic medications25
• Females have higher rates of hematoma after radial PCI31
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